CMAB008 not checked
Taizhou Mabtech Pharmaceutical Co.,Ltd
FollowEvery change as it happens, and a Monday email
Trials
28 active
31 in total · 30 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Crohn Disease
- Main trialPhase 4
- “Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.”In the company’s words, NCT05906576 on ClinicalTrials.gov
- Other names
- Infliximab
Other drugs for Crohn Disease
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- UpadacitinibAbbVie · Phase 3
- TirzepatideEli Lilly · Phase 3
- JNJ-78934804Johnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 2/3
Coming up1
- NovPhase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials31
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Nov 2026 | Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients | |
| Phase 4Authorised | not given | Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis | |
| Phase 2Authorised | not given | Infliximab for non-Crohn Anal Fistulas | |
| Phase 3Authorised | not given | Efficacy and safety of infliximab for immune checkpoint inhibitor induced colitis: a multinational, randomised, open label, phase III trial - The iCaD Study | |
| Phase 4Authorised | not given | Model-informed precision dosing during infliximab rescue therapy for patients with steroid-refractory acute severe ulcerative colitis: an exploratory study | |
| Phase 2Authorised | not given | Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial. | |
| Phase 2Authorised | not given | Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING). | |
| Phase 2Authorised | not given | Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis (RESPECT). | |
| Phase 4Authorised | not given | Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patients (Pro-RAPID) | |
| Phase 4Authorised | not given | Subcutaneous Infliximab After A Previous Intravenous Dose Optimization | |
| Phase 4Authorised | not given | Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL trial | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 3Ended | not given | Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients with Active Crohn’s Disease or Ulcerative Colitis | |
| Phase 4Ended | not given | PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach | |
| Phase 2Authorised | not given | INTOReTAK - Multicentre, randomized, prospective trial evaluating the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis - INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis | |
| Phase 4Authorised | not given | Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis | |
| Phase 4Authorised | not given | Stopping anti-TNF treatment in Crohn's and Colitis patients in remission | |
| Phase 3Authorised | not given | FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial | |
| Phase 4Authorised | not given | FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 3Authorised | not given | TAWIS - Evaluation of TNF-alpha antagonists (Infliximab) withdrawal in sarcoidosis : a prospective, randomized, controlled trial. | |
| Phase 4Ended | not given | A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn’s Disease ( Direct-CD) | |
| Phase 3/4Authorised | not given | IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS | |
| Phase 4Authorised | not given | Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial | |
| Phase 4Authorised | not given | Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE) | |
| Phase 2Authorised | not given | Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial | |
| Phase 4Authorised | not given | Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference | |
| Phase 4Authorised | not given | DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial | |
| Phase 4Authorised | not given | Subcutaneous Infliximab for perianal fistulizing Crohn’s disease | |
| Phase 3Authorised | not given | A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026